Saturday 17 October 2026
Export CSCIF’s income statement to Excel — free account
COSCIENS Biopharma Inc.
CSCIF Healthcare Biotechnology
COSCIENS Biopharma Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 21.8% from fiscal 2024. In the quarter to June 2026, revenue grew 30.0%, EPS grew 92.6% and free cash flow grew 113.3%, each against the same quarter a year earlier.
6.49
0.24
+3.84%
Follow CSCIF
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.77 | 0.00 | 0.00 |
Piotroski F-Score |
3 | 4 | 5 | 2 | 4 | 6 | 1 | 7 | 2 | 3 |
P/S ratio |
0.29 | 0.25 | 0.65 | 0.92 | 2.62 | 1.61 | 9.97 | 0.60 | 12.81 | 13.25 |
Altman Z-Score |
(2.08) | (1.19) | 1.43 | (8.41) | (4.89) | (11.73) | (23.41) | (14.04) | (22.73) | (15.23) |
Altman Z″-Score (non-manufacturers) |
(3.75) | (0.66) | 10.19 | (14.79) | (7.13) | (24.82) | (53.54) | (34.85) | (52.18) | (32.85) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.12 | 0.00 | 0.00 |
P/Operating CF |
(1.48) | (0.79) | (4.27) | (1.52) | (5.71) | 2.34 | (1.80) | 2.36 | (2.61) | (1.49) |
Beneish M-Score |
(2.95) | 1.32 | (0.20) | (4.07) | (2.42) | 2.12 | 96.99 | 21.33 | (1.42) | (1.55) |
P/B ratio |
0.57 | 0.18 | 0.22 | 0.15 | 0.26 | 0.45 | 0.00 | 8.45 | 0.00 | 1.94 |
Price to Tangible BV |
1.07 | 0.21 | 0.22 | 0.18 | 0.31 | 1.36 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
(0.68) | (1.46) | (0.29) | (8.05) | (9.79) | (5.03) | (4.76) | 0.06 | 4.38 | (10.89) |
EV/EBITDA |
0.55 | 0.85 | 0.64 | 2.70 | 5.05 | 4.36 | 0.25 | 0.19 | 0.00 | 0.34 |
EV/Operating CF |
0.61 | 0.96 | 0.79 | 3.32 | 6.00 | 4.45 | 0.24 | 0.11 | (0.18) | 0.34 |
EV/FCF |
0.60 | 0.92 | 0.71 | 3.17 | 5.59 | 4.48 | 0.24 | 0.11 | (0.18) | 0.34 |
Quick Ratio |
2.37 | 2.61 | 5.32 | 7.49 | 8.88 | 5.60 | 1.50 | 2.65 | 1.39 | 5.32 |
Current Ratio |
3.18 | 3.32 | 8.59 | 7.88 | 9.12 | 5.82 | 1.93 | 2.90 | 1.63 | 5.41 |
Net Debt/EBITDA |
0.78 | 1.00 | 2.10 | 3.01 | 6.40 | 5.76 | 0.78 | (1.56) | 0.33 | 0.74 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.27 | 0.33 | 0.18 | 0.08 | 0.09 | 0.13 | 0.02 | 1.14 | 0.03 | 0.02 |
Operating CF/Net income |
0.82 | 0.95 | 0.74 | 0.60 | 1.03 | 0.81 | 1.78 | 1.63 | 1.36 | 1.16 |
Capex/Depreciation |
(0.43) | (1.55) | (0.12) | 0.01 | 0.42 | 0.00 | 0.00 | (0.03) | (0.43) | 0.98 |
Interest Coverage |
(62.15) | (133.48) | (34.04) | (5,084.33) | (412.90) | (7.75) | — | — | — | — |
| (121.84%) | (89.54%) | (12.27%) | (51.21%) | (25.28%) | (95.24%) | 2,173.38% | (955.94%) | (979.64%) | (179.39%) | |
| (36.66%) | (52.06%) | (8.74%) | (33.39%) | (14.29%) | (17.96%) | (26.86%) | 17.74% | (62.38%) | (60.03%) | |
ROIC |
0.00% | 0.00% | (20.15%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(58.54%) | (55.22%) | (16.13%) | (46.71%) | (13.23%) | (22.36%) | (114.30%) | 39.04% | (452.36%) | (133.16%) |
Average Days of Receivables |
61.39 | 94.08 | 14.82 | 139.79 | 255.01 | 228.08 | 451.45 | 3.99 | 87.39 | 146.24 |
Research and Development Expense of Revenue |
39.34% | 86.62% | 28.56% | 221.74% | 124.98% | 41.24% | 345.30% | 10.91% | 1,159.70% | 1,810.65% |
Selling, General and Administrative Expense of Revenue |
134.20% | 108.98% | 77.38% | 145.92% | 138.16% | 161.36% | 1,471.62% | 44.65% | 1,440.20% | 1,524.92% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.11 | 0.24 | 0.40 | 0.33 | 0.39 | 0.24 |
Share Based Compensation of Revenue |
(0.16%) | 4.84% | 2.69% | 9.65% | 5.91% | 1.67% | 149.06% | 2.12% | 19.72% | 118.77% |
Graham Net Nets |
(2.80) | 0.87 | 1.85 | 6.76 | 3.17 | 0.65 | (2.17) | (0.42) | (1.32) | (0.22) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 320.42 | 247.14 | 652.26 | 0.00 |
Earnings Yield |
(476.26%) | (584.69%) | (360.89%) | (431.41%) | (59.34%) | (104.66%) | (118.69%) | 26.53% | (143.05%) | (205.73%) |
Free Cash Flow Yield |
(391.38%) | (642.07%) | (62.08%) | (274.41%) | (66.86%) | (69.78%) | (199.03%) | 89.40% | (192.42%) | (240.78%) |
Revenue per Share |
7.11 | 11.15 | 11.60 | 13.94 | 13.73 | 26.68 | 9.13 | 490.53 | 18.50 | 26.41 |
Operating CF per Share |
(8.03) | (16.94) | (4.19) | (33.81) | (22.40) | (30.16) | (183.96) | 124.54 | (459.18) | (840.87) |
Capex per Share |
(0.44) | (1.35) | (0.28) | (0.03) | (1.67) | 0.04 | 0.00 | 0.27 | 3.15 | (1.86) |
Free Cash Flow per Share |
(8.47) | (18.29) | (4.48) | (33.84) | (24.07) | (30.12) | (183.96) | 124.82 | (456.03) | (842.72) |
Cash per Share |
6.93 | 19.06 | 10.85 | 125.09 | 170.50 | 177.29 | 134.44 | 264.82 | 155.91 | 637.65 |
Shareholders Equity per Share |
3.64 | 15.30 | 34.17 | 88.42 | 138.34 | 96.50 | (42.25) | 34.80 | (55.77) | 180.06 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.64 | 15.30 | 34.17 | 88.42 | 138.34 | 96.50 | (42.25) | 34.80 | (55.77) | 180.06 |
Free Cash Flow |
(8.93) | (15.73) | (2.75) | (13.69) | (9.22) | (4.12) | (10.72) | 6.84 | (22.76) | (29.07) |
Working Capital |
7.89 | 16.76 | 9.96 | 48.44 | 63.05 | 22.87 | 5.25 | 10.66 | 3.61 | 18.54 |
Capital Expenditures |
(0.46) | (1.16) | (0.17) | (0.01) | (0.64) | 0.01 | — | 0.02 | 0.16 | (0.06) |
Net Current Asset Value |
(6.09) | 2.07 | 8.56 | 35.24 | 43.70 | 3.82 | (11.53) | (6.85) | (15.60) | (2.70) |
EV/EBIT |
0.49 | 0.81 | 0.44 | 2.98 | 5.94 | 3.22 | 0.25 | 0.16 | 0.00 | 0.34 |
Capex to Sales |
0.06 | 0.12 | 0.02 | 0.00 | 0.12 | 0.00 | 0.00 | 0.00 | (0.17) | 0.07 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.64 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.11 | 0.07 | 0.12 | (7.26) | (7.94) | 67.68 | 6.89 | (8.48) | (3.60) | (0.32) |
Cash ROIC |
(80.14%) | (53.22%) | (9.94%) | (15.85%) | (7.79%) | (11.00%) | (199.53%) | 41.66% | (455.39%) | (103.06%) |
Accounts Receivable Turnover |
4.02 | 6.94 | 5.83 | 1.93 | 1.77 | 2.48 | 1.12 | 104.39 | 3.15 | 1.89 |
Accounts Payable Turnover |
1.47 | 1.69 | 1.74 | 0.05 | 0.04 | 1.07 | 0.17 | 0.75 | 0.00 | 0.00 |
Inventory Turnover |
2.43 | 1.45 | 1.98 | 1.04 | 1.91 | 3.79 | 0.57 | 5.30 | — | — |
Average Days of Payables |
141.68 | 355.38 | 87.84 | 8,899.49 | 10,836.44 | 346.41 | 1,912.24 | 484.18 | 0.00 | 0.00 |
Days of Inventory on Hand |
98.34 | 202.19 | 347.99 | 532.39 | 296.06 | 3.31 | 1,070.96 | 41.64 | 0.00 | — |
Average Receivables |
1.87 | 1.38 | 1.23 | 2.92 | 2.98 | 1.47 | 0.48 | 0.26 | 0.29 | 0.48 |
Average Payables |
3.31 | 2.87 | 2.42 | 3.25 | 2.44 | 2.17 | 2.47 | 2.80 | 3.28 | 3.96 |
Average Inventory |
2.00 | 3.35 | 2.12 | 0.15 | 0.05 | 0.61 | 0.72 | 0.40 | — | — |
Average Assets |
28.25 | 29.41 | 39.89 | 68.06 | 58.55 | 28.49 | 22.50 | 23.60 | 26.93 | 41.58 |
Average Common Equity |
8.50 | 17.10 | 28.41 | 44.38 | 33.10 | 5.37 | (0.28) | (0.44) | 1.71 | 13.91 |
Columns are period end dates